Characteristics of COVID-19 vaccinated and unvaccinated patients admitted to Careggi University Hospital, Florence, Italy.

Breakthrough infection COVID-19 serological testing Covid-19 Hospitalisation Mortality SARS-CoV-2 vaccines

Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
04 2023
Historique:
received: 15 10 2022
accepted: 14 02 2023
medline: 11 4 2023
pubmed: 1 3 2023
entrez: 28 2 2023
Statut: ppublish

Résumé

More than 11.5 billion COVID-19 vaccine doses have been administered around the world. Although vaccine effectiveness for severe infections is reported to be 89.0%, breakthrough infections are common and may lead to severe outcome in fragile population. We conducted a real-world observational study on 420 COVID-19 admitted patients from July 2021 to January 2022 in a tertiary level Italian hospital. We collected patient's vaccination and SARS-CoV-2 serological status, SARS-CoV-2 treatments, oxygen supports, intensive (ICU) and subintensive (sub-ICU) care unit admissions, length of staying (LoS) and in-hospital mortality. One-hundred-seventy-two vaccinated and 248 unvaccinated patients were admitted during the study period. Vaccinated group (Vg) had a significantly more elevated Charlson Comorbidity Index than Unvaccinated group (UVg), and no statistical differences were found in terms of in-hospital mortality, LoS or ICU and sub-ICU admissions. Among Vg, anti-S antibodies were detected in 86.18% of patients (seropositives). Vaccinated seronegative patients' in-hospital mortality was significantly higher than vaccinated seropositive patients (33.33% vs 10.69%, p = 0.0055): in particular, mortality rate in 45-69 years old population was higher in vaccinated seronegative group, and comparable in patients ≥ 70 years old. No differences in terms of outcome were registered between Vg and UVg, taking into account that Vg was considerably older and with more comorbidities. In line with other recent observations, higher mortality rate was evidenced for seronegative vaccinated patients. Primary prophylaxis and early treatments result to be necessary, especially for older and immunosuppressed populations.

Identifiants

pubmed: 36853393
doi: 10.1007/s11739-023-03231-w
pii: 10.1007/s11739-023-03231-w
pmc: PMC9972322
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

821-830

Informations de copyright

© 2023. The Author(s).

Références

Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Lancet Infect Dis. 2021 Nov;21(11):1485-1486
pubmed: 34506735
Nat Med. 2022 May;28(5):934-938
pubmed: 35210596
Int J Infect Dis. 2022 Sep;122:420-426
pubmed: 35750265
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
BMJ. 2022 Mar 17;376:o722
pubmed: 35301227
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Lancet. 2021 Nov 13;398(10313):1799-1800
pubmed: 34756204
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Am J Infect Control. 2021 Jul;49(7):900-906
pubmed: 33347937
Ann Rheum Dis. 2022 Jun;81(6):868-874
pubmed: 35135831
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Lancet Rheumatol. 2022 Jun;4(6):e379-e380
pubmed: 35527809
Clin Infect Dis. 2021 Dec 6;73(11):e4329-e4335
pubmed: 33009907
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Lancet Respir Med. 2022 Oct;10(10):985-996
pubmed: 35688164
JAMA Intern Med. 2022 Feb 1;182(2):153-162
pubmed: 34962505
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Reg Health Am. 2021 Dec;4:100065
pubmed: 34522911
Front Microbiol. 2022 Jan 18;12:796807
pubmed: 35116013
J Biomed Sci. 2022 Jan 4;29(1):1
pubmed: 34983527
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1182-1189
pubmed: 36107788
Clin Microbiol Infect. 2022 Jun;28(6):871-878
pubmed: 35219807
Int J Infect Dis. 2022 Jan;114:252-260
pubmed: 34800687
RMD Open. 2022 Apr;8(1):
pubmed: 35387864
Age (Dordr). 2013 Dec;35(6):2357-66
pubmed: 23354682
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
J Mol Graph Model. 2022 Jan;110:108042
pubmed: 34653812

Auteurs

Riccardo Paggi (R)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Anna Barbiero (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Tommaso Manciulli (T)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Andreea Miftode (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Marta Tilli (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Filippo Lagi (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Jessica Mencarini (J)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Beatrice Borchi (B)

Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Marco Pozzi (M)

Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Filippo Bartalesi (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Michele Spinicci (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Lorenzo Martini (L)

Internal Medicine Unit 2, Careggi University Hospital, Florence, Italy.

Alessandra Coppola (A)

Internal Medicine Unit 2, Careggi University Hospital, Florence, Italy.

Carlo Nozzoli (C)

Internal Medicine Unit 1, Careggi University Hospital, Florence, Italy.

Adriano Peris (A)

Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

Manuela Bonizzoli (M)

Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

Filippo Pieralli (F)

High-Intensity Internal Medicine Unit, Careggi University Hospital, Florence, Italy.

Alessandro Bartoloni (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Lorenzo Zammarchi (L)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. lorenzo.zammarchi@unifi.it.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy. lorenzo.zammarchi@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH